Evidence map›Paper›PMID 34963185›Full record

ArticleThrombosis and haemostasis2022

Effectiveness and Safety of Apixaban versus Warfarin in Venous Thromboembolism Patients with Chronic Kidney Disease.

Alexander T Cohen, Janvi Sah, Amol D Dhamane, Theodore Lee, Lisa Rosenblatt, Patrick Hlavacek, Birol Emir, Rachel Delinger, Huseyin Yuce, Xuemei Luo

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Thrombosis and haemostasis, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed, 1 pooled it
4.9field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 1 synthesis or guideline pooled it, 41 citations in OpenAlex.

  1. Pooled it
  2. Anticoagulation in Advanced Chronic Kidney Disease: Navigating Uncertainty.Turkish journal of haematology : official journal of Turkish Society of Haematology · 2026
    Review
  3. Article
  4. Observational
  5. Comparative safety of oral anticoagulants in severe renal impairment.Research and practice in thrombosis and haemostasis · 2026
    Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 2 countries.

Alexander T CohenDepartment of Hematological Medicine, Guy's & St. Thomas' NHS Foundation Trust, King's College London, London, United Kingdom.
Janvi SahSIMR, LLC, Ann Arbor, Michigan, United States.
Amol D DhamaneBristol Myers Squibb Company, Lawrenceville, New Jersey, United States.
Theodore LeePfizer Inc., New York, New York, United States.
Lisa RosenblattBristol Myers Squibb Company, Lawrenceville, New Jersey, United States.
Patrick HlavacekPfizer Inc., New York, New York, United States.
Birol EmirPfizer Inc., New York, New York, United States.
Rachel DelingerSIMR, LLC, Ann Arbor, Michigan, United States.
Huseyin YuceDepartment of Mathematics, New York City College of Technology, City University of New York, New York, New York, United States.
Xuemei LuoPfizer Inc., Groton, Connecticut, United States.
Pfizer (United States) · USBristol-Myers Squibb (United States) · USMichigan United · USKing's College London · GBNew York City College of Technology · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

There has been limited evidence reported about the outcomes of oral anticoagulants among patients with venous thromboembolism (VTE) and chronic kidney disease (CKD), especially those with stage V/end-stage renal disease (ESRD). This retrospective cohort analysis of five U.S. claims databases evaluated the risk of recurrent VTE, major bleeding (MB), and clinically relevant nonmajor bleeding (CRNMB) for apixaban versus warfarin among VTE patients diagnosed with CKD, including ESRD. Inverse probability treatment weighting (IPTW) was used to balance patient characteristics between treatment cohorts. Hazard ratios (HRs) were calculated for recurrent VTE, MB, and CRNMB among patients with CKD who experienced an index VTE. An interaction analysis was conducted to evaluate treatment effects across different stages of CKD. A total of 29,790 VTE patients with CKD were selected for analyses, of whom 10,669 (35.8%) initiated apixaban and 19,121 (64.2%) initiated warfarin. Among IPTW-balanced patient cohorts, the apixaban group had significantly lower risk of recurrent VTE (HR: 0.78; 95% confidence interval [CI]: 0.66-0.92), MB (HR: 0.76; 95% CI: 0.65-0.88), and CRNMB (HR: 0.86; 95% CI: 0.80-0.93) than the warfarin group. When stratified by CKD stage (stage I/II: 8.2%; stage III: 49.4%; stage IV: 12.8%; stage V/ESRD: 12.0%; stage unspecified: 17.6%), no significant interaction was observed for effects of apixaban versus warfarin on recurrent VTE or MB. In summary, apixaban was associated with a significantly lower risk of recurrent VTE and MB than warfarin among VTE patients with CKD. CKD stages did not have significant impact on treatment effects for recurrent VTE and MB.

Indexed as

Kidney Failure, ChronicRenal Insufficiency, ChronicVenous ThromboembolismAnticoagulantsHemorrhageHumansPyrazolesPyridonesRetrospective StudiesWarfarinAnticoagulantsapixabanPyrazolesPyridonesWarfarin

Identifiers

PMID34963185
PMCPMC9251708
OpenAlexW4200085215

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.